Patent 9512119 was granted and assigned to Sato Pharmaceutical on December, 2016 by the United States Patent and Trademark Office.
The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound.